Voglimit 0.2 Tablet 15: Uses, Side Effects, Price & Substitutes

About Voglimit 0.2 Tablet 15

Voglimit 0.2 Tablet 15 is primarily used to manage type 2 diabetes mellitus. This oral medication belongs to a group of medicines known as alpha-glucosidase inhibitors.

In addition to its primary use, this medicine can help prevent long-term complications associated with uncontrolled diabetes. These include kidney damage, blindness, nerve problems, limb amputations, and cardiovascular disease.

Before starting this medication, it's important to consult your doctor for the correct dosage and frequency. Make sure you inform your doctor about any pre-existing conditions you have or any ongoing medications you are taking. If you experience any side effects while on this medicine, notify your doctor immediately. For optimal results, continue taking the medicine for the duration prescribed by your doctor.

Frequently Asked Questions (FAQs)

What is Voglimit 0.2 Tablet 15 used for?

Voglimit 0.2 Tablet 15 is used to manage type 2 diabetes mellitus. As an alpha-glucosidase inhibitor, it helps control blood sugar levels, particularly after meals, when diet and exercise alone are not enough. In addition to managing blood glucose, it also helps prevent long-term complications of uncontrolled diabetes, such as kidney damage, nerve problems, blindness, and cardiovascular diseases.

What does Voglimit 0.2 Tablet 15 do?

Voglimit 0.2 Tablet 15 works by slowing down the digestion of carbohydrates, reducing the rise in blood sugar levels after meals.

How should I use Voglimit 0.2 Tablet 15?

You should take Voglimit 0.2 Tablet 15 orally just before each main meal. It's important to swallow the tablet whole with a glass of water.

Can I take other diabetes medicines with Voglimit 0.2 Tablet 15?

Yes, you can take Voglimit 0.2 Tablet 15 with other diabetes medicines like insulin and metformin, but always consult your doctor for proper dosage adjustments.

What should I do if I miss a dose of Voglimit 0.2 Tablet 15?

If you miss a dose, take it as soon as you remember unless it's nearly time for your next scheduled dose. Never double up on doses to compensate for the missed one.

Are there any side effects of using Voglimit 0.2 Tablet 15?

Common side effects include abdominal pain, diarrhoea, and flatulence, which usually subside over time. Consult a doctor if you experience any persistent side effects.

Can pregnant or breastfeeding women take Voglimit 0.2 Tablet 15?

Exercise caution if you are taking Voglimit 0.2 Tablet 15 during pregnancy or while breastfeeding. Always consult your doctor before taking this medicine.

References

National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 444020, Voglibose. https://pubchem.ncbi.nlm.nih.gov/compound/Voglibose
Dabhi, A. S., Bhatt, N. R., & Shah, M. J. (2013). Voglibose: an alpha glucosidase inhibitor. Journal of clinical and diagnostic research: JCDR, 7(12), 3023–3027. https://doi.org/10.7860/JCDR/2013/6373.3838
DrugBank Online. (2021, Jun 19). Voglibose. https://go.drugbank.com/drugs/DB04878
Matsumoto, K., Yano, M., Miyake, S., Ueki, Y., Yamaguchi, Y., Akazawa, S., & Tominaga, Y. (1998). Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes care, 21(2), 256–260. https://doi.org/10.2337/diacare.21.2.256
Göke, B., Fuder, H., Wieckhorst, G., Theiss, U., Stridde, E., Littke, T., Kleist, P., Arnold, R., & Lücker, P. W. (1995). Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion, 56(6), 493–501. https://doi.org/10.1159/000201282
Kurebayashi, S., Watada, H., Tanaka, Y., Kawasumi, M., Kawamori, R., & Hirose, T. (2006). Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study. Endocrine journal, 53(2), 213–217. https://doi.org/10.1507/endocrj.53.213
Saito, N., Sakai, H., Suzuki, S., Sekihara, H., & Yajima, Y. (1998). Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients. The Journal of international medical research, 26(5), 219–232. https://doi.org/10.1177/030006059802600501

Disclaimer

We, at Truemeds make a diligent attempt to deliver accurate, expert- drafted and thoroughly reviewed medicine related information to our consumers. However, it should, by no means, be considered a substitute for prescription from a certified doctor or a trustworthy doctor-patient relationship. In fact we detest any form of self medication without expert advice. The sole purpose of the information on our portal is to educate our consumers, which helps improve the communication between a doctor and a patient. The information by no means is complete in its entirety and should not be used to diagnose or treat any medical condition. No amount of information can replace the experience and expertise of a doctor, therefore his/her advice always holds priority and should be followed appropriately.